SEC Form 4 · accession 0001447348-15-000007
PROGENICS PHARMACEUTICALS INC · PGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Robert Baker
Officer — CEO · Director
Period of report
Mar 2, 2015
Accepted (ET)
Mar 4, 2015 · 9:54 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000835887
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $6.65 | Mar 2, 2015 | A | 132,000 | A | — | Mar 2, 2025 | Common Stock | 132,000 | 132,000 | D |
Explanation of responses
- F1The stock options become exercisable in three equal annual installments, commencing one year from the grant date.